Breitenstein, A.; Gay, A.; Vogtländer, K.; Fox, K.A.A.; Steffel, J., on behalf of the XATOA Publication Committee.
The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis” Registry. J. Clin. Med. 2024, 13, 1956.
https://doi.org/10.3390/jcm13071956
AMA Style
Breitenstein A, Gay A, Vogtländer K, Fox KAA, Steffel J on behalf of the XATOA Publication Committee.
The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis” Registry. Journal of Clinical Medicine. 2024; 13(7):1956.
https://doi.org/10.3390/jcm13071956
Chicago/Turabian Style
Breitenstein, Alexander, Alain Gay, Kai Vogtländer, Keith A. A. Fox, and Jan Steffel on behalf of the XATOA Publication Committee.
2024. "The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis” Registry" Journal of Clinical Medicine 13, no. 7: 1956.
https://doi.org/10.3390/jcm13071956
APA Style
Breitenstein, A., Gay, A., Vogtländer, K., Fox, K. A. A., & Steffel, J., on behalf of the XATOA Publication Committee.
(2024). The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis” Registry. Journal of Clinical Medicine, 13(7), 1956.
https://doi.org/10.3390/jcm13071956
